Vir Biotechnology (VIR) Return on Capital Employed (2019 - 2026)
Vir Biotechnology recorded quarterly Return on Capital Employed of 50.19% in Q1 2026, up 3.85% quarter-over-quarter from 52.2% in Q4 2025, and up 299.0% year-over-year from 12.58% in Q1 2025.
Vir Biotechnology's Return on Capital Employed history runs 8 years deep, the most recent figure standing at 50.19% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 299.0% year-over-year to 50.19%; the TTM figure through Mar 2026 stood at 50.19% (up 299.0% YoY), while the FY2025 annual figure was 43.26%, down 511.0% from the prior year.
- Return on Capital Employed came in at 50.19% for Q1 2026 at Vir Biotechnology, up from 52.2% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 92.72% in Q1 2022 to a low of 53.22% in Q3 2025.
- A 5-year average of 15.6% and a median of 35.24% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 15032 bps in 2022 and sank 10713 bps in 2023, its largest moves.
- Vir Biotechnology's Return on Capital Employed stood at 37.22% in 2022, then sank by 202 bps to 37.88% in 2023, then declined by 17 bps to 44.18% in 2024, then retreated by 18 bps to 52.2% in 2025, then grew by 4 bps to 50.19% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 50.19%, 52.2%, and 53.22% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | -50.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.19% |
| Dec 31, 2025 | -52.20% |
| Sep 30, 2025 | -53.22% |
| Jun 30, 2025 | -52.96% |
| Mar 31, 2025 | -53.18% |
| Dec 31, 2024 | -44.18% |
| Sep 30, 2024 | -41.52% |
| Jun 30, 2024 | -34.52% |
| Mar 31, 2024 | -35.24% |
| Dec 31, 2023 | -37.88% |
| Sep 30, 2023 | -35.15% |
| Jun 30, 2023 | -14.09% |
| Mar 31, 2023 | -14.41% |
| Dec 31, 2022 | 37.22% |
| Sep 30, 2022 | 66.20% |
| Jun 30, 2022 | 57.44% |
| Mar 31, 2022 | 92.72% |
| Dec 31, 2021 | 33.90% |
| Sep 30, 2021 | -28.82% |
| Jun 30, 2021 | -30.89% |
| Mar 31, 2021 | -57.61% |
| Dec 31, 2020 | -35.70% |
| Sep 30, 2020 | -34.53% |
| Jun 30, 2020 | -40.87% |
| Mar 31, 2020 | -50.00% |
| Dec 31, 2019 | -43.61% |